medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2013, Number 2

<< Back Next >>

Ann Hepatol 2013; 12 (2)

Prevalence and risk factors of isolated anti-HBc antibody and occult hepatitis B infection in hemodialysis patients: a nationwide study

Keyvani H, Agah S, Kabir A, Seyed-Moayed A

Language: English
References: 30
Page: 213-219
PDF size: 92.55 Kb.


ABSTRACT

Background. Recent studies have demonstrated that prevention of hepatitis B virus (HBV) transmission remains a challenge in hemodialysis (HD) patients. The aim of this study is to explore factors which increase the possibility of occult HBV (OHB) infection in patients under HD in Iran. Material and methods. Among 2188 cases who spent an average of 60.2 ± 61.1 months under HD, we selected 103 cases with isolated antihepatitis B virus core antibody (anti-HBc) and 231 controls without any HBV, hepatitis D virus (HDV) and hepatitis C virus (HCV) serologic markers. Socio-demographic data, past medical history, and clinical signs and symptoms were assessed. Results. The frequency of checking hepatitis B serologic markers was 15.3%. The rate of OHB infection in HD patients who were monitored for their HBV markers was 4.9%. Cases with isolated anti-HBc had significantly higher percentage of positive HBV DNA [odds ratio: OR (95% confidence interval: 95% CI) = 12.1 (1.4-105)], visual disturbances [OR (95% CI) = 1.8 (1.1-3.03)], history of diabetes mellitus [OR (95% CI) = 2.1 (1.3-3.5)], higher age, higher age when dialysis started and were mostly married, illiterate, disabled and retired. Diabetes mellitus was the only independent predictor of HBV DNA status in cases with isolated anti-HBc. Conclusion. In our region, OHB infection is prevalent among hemodialysis patients and displays a direct correlation with factors which are age related except diabetes mellitus. Thus, the presence of isolated anti-HBc should prompt the clinician to evaluate a possible OHB infection especially when it is detected in conjunction with a history of diabetes mellitus.


REFERENCES

  1. Raimondo G, Pollicino T, Romano L, Zanetti AR. A 2010 update on occult hepatitis B infection. Pathol Biol (Paris) 2010; 58: 254-7.

  2. Kabir A, Keshvari M, Kashani AH, Alavian SM. Predicting response to HBV vaccination in people with positive anti- HBc but negative HBsAg and anti-HBs. Hum Vaccin 2008; 4: 379-83.

  3. Mahdavimazdeh M, Hosseini-Moghaddam SM, Alavian SM, Yahyazadeh H. Hepatitis B Infection in Hemodialysis Patients in Tehran Province, Iran. Hepat Mon 2009; 9: 206-10.

  4. Fabrizi F, Bunnapradist S, Lunghi G, Aucella F, Martin P. Epidemiology and clinical significance of hepatotropic infections in dialysis patients. Minerva Urol Nephrol 2004; 56: 249-57.

  5. Fabrizi F, Lunghi G, Martin P. Hepatitis B virus infection in hemodialysis: Recent discoveries. J Nephrol 2002; 15: 463-8.

  6. Alavian SM, Hajarizadeh B, Ahmadzad-Asl M, Kabir A, Bagheri- Lankarani K. Hepatitis B Virus Infection in Iran: A Systematic Review. Hepat Mon 2008; 8: 281-94.

  7. Merat S, Malekzadeh R, Rezvan H, Khatibian M. Hepatitis B in Iran. Arch Irn Med 2000; 3: 192-201.

  8. Alavian SM, Bagheri-Lankarani K, Mahdavi-Mazdeh M, Nourozi S. Hepatitis B and C in dialysis units in Iran: changing the epidemiology. Hemodial Int 2008; 12: 378-82.

  9. Mostaghni AA, Soltanian A, Mokhtari E, Japoni S, Mehrabani D. Seroprevalence of hepatitis B virus among hemodialysis patients in Bushehr province, southern Iran. Hepat Mon 2011; 11: 200-2.

  10. Aghakhani A, Banifazl M, Kalantar E, Eslamifar A, Ahmadi F, Razeghi E, Atabak S, et al. Occult hepatitis B virus infection in hemodialysis patients with isolated hepatitis B core antibody: a multicenter study. Ther Apher Dial 2010; 14: 349-53.

  11. Hollinger FB, Habibollahi P, Daneshmand A, Alavian SM. Occult Hepatitis B Infection in Chronic Hemodialysis Patients: Current Cocepts and Strategy. Hepat Mon 2010; 10: 199-204.

  12. Edey M, Barraclough K, Johnson DW. Review article: Hepatitis B and dialysis. Nephrology (Carlton) 2010; 15: 137-45.

  13. Mahdavi-Mazdeh M, Zamyadi M, Nafar M. Assessment of management and treatment response in hemodialysis patients in Tehran province, Iran. Nephrol Dial Transplant 2008; 23: 288-93.

  14. Available from: http://www.amar.org.ir/default-2649.aspx [Accessed 31 Oct 2010].

  15. Allain JP, Hewitt PE, Teddler RS, Williamson LM. Evidence that anti-HBc but not HBV DNA testing may prevent some HBV transmission by transfusion. Br J Haematol 1999; 107: 186-95.

  16. Douglas DD, Taswell HF, Rakela J, Rabe D. Absence of hepatitis B virus DNA detected by polymerase chain reactionin blood donors who are hepatitis B surface antigen negative and antibody to hepatitis B core antigen positive from a United States population with a low prevalence of hepatitis B serologic markers. Transfusion 1993; 33: 212-6.

  17. Wang JT, Wang TH, Sheu JC, Shih LN, Lin JT, Chen DS. Detection of hepatitis B virus DNA by polymerase chain reaction in plasma of volunteer blood donors negative for hepatitis B surface antigen. J Infect Dis 1991; 163: 397-9.

  18. Kleinman SH, Kuhns MC, Todd DS, Glynn SA, McNamara A, Di Marco A, Busch MP. Frequency of HBV DNA detection in US blood donors testing positive for the presence of anti-HBc: implications for transfusion transmission and donor screening. Transfusion 2003; 43: 696-704.

  19. Arababadi MK, Hassanshahi G, Yousefi H. HBV-DNA in hemodialysis patients infected by HCV. Saudi J Kidney Dis Transpl 2009; 20: 398-401.

  20. Moreira RC, Deguti MM, Lemos MF, Saraceni CP, Oba IT, Spina AM, Nascimento-Lima AS, et al. HBV markers in haemodialysis Brazilian patients: a prospective 12-month follow-up. Mem Inst Oswaldo Cruz 2010; 105: 107-8.

  21. Altindis M, Uslan I, Cetinkaya Z, Yüksel S, Ciftçi IH, Demirtürk N, Ozdemir M, et al. Investigation of hemodialysis patients in terms of the presence of occult hepatitis B. Mikrobiyol Bul 2007; 41: 227-33.

  22. Yakaryilmaz F, Gurbuz OA, Guliter S, Mert A, Songur Y, Karakan T, Keles H. Prevalence of occult hepatitis B and hepatitis C virus infections in Turkish hemodialysis patients. Ren Fail 2006; 28: 729-35.

  23. Fabrizi F, Messa PG, Lunghi G, Aucella F, Bisegna S, Mangano S, Villa M, et al. Occult hepatitis B virus infection in dialysis patients: a multicentre survey. Aliment Pharmacol Ther 2005; 21: 1341-7.

  24. Loza Munárriz C, Depaz Dolores M, Suarez Jara M, Loza Munárriz R, Valenzuela Córdova R, Bravo Tejada J, Valencia Rodriguez J, et al. Rate of serological markers of hepatitis B and C viruses in first-time users of the hemodialysis program at Hospital Nacional Cayetano Heredia (HNCH). Rev Gastroenterol Peru 2005; 25:320-7.

  25. Di Stefano M, Volpe A, Stallone G, Tartaglia L, Prato R, Martinelli D, Pastore G, et al. Occult HBV infection in hemodialysis setting is marked by presence of isolated antibodies to HBcAg and HCV. J Nephrol 2009; 22: 381-6.

  26. Elghannam DM, Aly RM, Goda EF, Eltoraby EE, Farag RE. Clinical significance of antibody to hepatitis B core antigen in multitransfused hemodialysis patients. Asian J Transfus Sci 2009; 3: 14-7.

  27. Gohar SA, Khalil RY, Elaish NM, Khedr EM, Ahmed MS. Prevalence of antibodies to hepatitis C virus in hemodialysis patients and renal transplant recipients. J Egypt Public Health Assoc 1995; 70: 465-84.

  28. Cendoroglo Neto M, Manzano SI, Canziani ME, Silva AE, Cirenza LF, Sesso Rde C, Ajzen H, et al. Environmental transmission of hepatitis B and hepatitis C viruses within the hemodialysis unit. Artif Organs 1995; 19: 251-5.

  29. Lai KN, Tam JS, Lai FM, Lin HJ. Isolated presence of antibody to hepatitis B core antigen in dialysis patients: occurrence of subclinical hepatitis? Am J Kidney Dis 1989; 13: 370-6.

  30. Ferreira RC, Teles SA, Dias MA, Tavares VR, Silva SA, Gomes SA, Yoshida CF, et al. Hepatitis B virus infection profile in hemodialysis patients in Central Brazil: prevalence, risk factors, and genotypes. Mem Inst Oswaldo Cruz 2006; 101: 689-92.




2020     |     www.medigraphic.com